Sarepta Therapeutics Balance Sheet Health
Financial Health criteria checks 4/6
Sarepta Therapeutics hat ein Gesamteigenkapital von $764.4M und eine Gesamtverschuldung von $1.2B, was einen Verschuldungsgrad von 161.8% ergibt. Die Gesamtaktiva und Gesamtpassiva betragen $3.1B bzw. $2.3B.
Key information
144.1%
Debt to equity ratio
US$1.24b
Debt
Interest coverage ratio | n/a |
Cash | US$1.68b |
Equity | US$859.34m |
Total liabilities | US$2.41b |
Total assets | US$3.26b |
Recent financial health updates
Does Sarepta Therapeutics (NASDAQ:SRPT) Have A Healthy Balance Sheet?
Nov 29Is Sarepta Therapeutics (NASDAQ:SRPT) Using Too Much Debt?
Aug 08Is Sarepta Therapeutics (NASDAQ:SRPT) Using Too Much Debt?
Apr 30Is Sarepta Therapeutics (NASDAQ:SRPT) Weighed On By Its Debt Load?
Jan 17Is Sarepta Therapeutics (NASDAQ:SRPT) Weighed On By Its Debt Load?
Aug 22Sarepta Therapeutics (NASDAQ:SRPT) Has Debt But No Earnings; Should You Worry?
May 09Recent updates
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Mar 02Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Fly 29% But Investors Aren't Buying For Growth
Feb 06Sarepta Therapeutics: Navigating Elevidys Towards FDA Approval
Jan 22Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Could Be 50% Below Their Intrinsic Value Estimate
Jan 10There's No Escaping Sarepta Therapeutics, Inc.'s (NASDAQ:SRPT) Muted Revenues
Dec 20Does Sarepta Therapeutics (NASDAQ:SRPT) Have A Healthy Balance Sheet?
Nov 29Is Sarepta Therapeutics (NASDAQ:SRPT) Using Too Much Debt?
Aug 08Is Sarepta Therapeutics (NASDAQ:SRPT) Using Too Much Debt?
Apr 30Is Sarepta Therapeutics (NASDAQ:SRPT) Weighed On By Its Debt Load?
Jan 17Sarepta Therapeutics seeks FDA accelerated approval for muscle wasting therapy SRP-9001
Sep 29Sarepta Therapeutics announces offering of $1B of convertible senior notes due 2027
Sep 12Sarepta says FDA lifted clinical hold on Duchenne candidate
Sep 06Is Sarepta Therapeutics (NASDAQ:SRPT) Weighed On By Its Debt Load?
Aug 22Sarepta inks licensing deal with Broad Institute for certain adeno-associated viruses
Aug 08Sarepta stock soars 19% on plans for US filing for gene therapy for neuromuscular disorder
Jul 29Sarepta Therapeutics (NASDAQ:SRPT) Has Debt But No Earnings; Should You Worry?
May 09Sarepta: The DMD Leader
Apr 26Sarepta: Still A Solid Long-Term Bet On Sales And Next Generation Treatments
Feb 09Is Sarepta Therapeutics (NASDAQ:SRPT) Using Debt In A Risky Way?
Feb 07A Look At The Intrinsic Value Of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)
Dec 06Sarepta: Revenue Keeps Rising While We Wait For Functional Data
Nov 01Health Check: How Prudently Does Sarepta Therapeutics (NASDAQ:SRPT) Use Debt?
Nov 01Is Sarepta Therapeutics (NASDAQ:SRPT) A Risky Investment?
Jul 19Sarepta Therapeutics: Faultlines May Run Deeper Than Assumed
Jun 02Most Shareholders Will Probably Agree With Sarepta Therapeutics, Inc.'s (NASDAQ:SRPT) CEO Compensation
May 27Sarepta Therapeutics EPS beats by $0.03, beats on revenue
May 05Financial Position Analysis
Kurzfristige Verbindlichkeiten: SRPTDie kurzfristigen Aktiva des Unternehmens ($2.5B) übersteigen seine kurzfristigen Passiva ($450.7M).
Langfristige Verbindlichkeiten: SRPTDie kurzfristigen Vermögenswerte des Unternehmens ($2.5B) übersteigen seine langfristigen Verbindlichkeiten ($1.9B).
Debt to Equity History and Analysis
Verschuldungsgrad: SRPT über mehr Barmittel verfügt als seine Gesamtverschuldung.
Schulden abbauen: SRPTDas Verhältnis von Schulden zu Eigenkapital ist in den letzten 5 Jahren von 64.9% auf 161.8% gestiegen.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stabile Start- und Landebahn für Bargeld: SRPT auf der Grundlage seines derzeitigen freier Cashflows über eine ausreichende Liquiditätsreserve für mehr als 3 Jahre verfügt.
Vorhersage Cash Runway: Unzureichende Daten, um festzustellen, ob SRPT über genügend Cash Runway verfügt, wenn sein freier Cashflow auf der Grundlage historischer Raten weiter wächst oder schrumpft.